RecruitingPhase 3NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Sponsor: Amgen
Seattle, WA · Spokane, WA · +138 more sites
3 recruiting obesity studies with a site in Spokane, WA.
Sponsor: Amgen
Seattle, WA · Spokane, WA · +138 more sites
Sponsor: Seattle Institute for Biomedical and Clinical Research
Seattle, WA · Spokane, WA · +3 more sites
Sponsor: Novo Nordisk A/S
Spokane, WA · +17 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.